SWOG
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Phase 2
Not yet recruiting
- Conditions
- Lung Small Cell Carcinoma, I SubtypeLung Small Cell Carcinoma, N SubtypeLung Small Cell Carcinoma, P SubtypeExtensive Stage Lung Small Cell CarcinomaLung Small Cell Carcinoma, A Subtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: Platinum CompoundProcedure: Positron Emission TomographyRadiation: Thoracic Radiation Therapy
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 900
- Registration Number
- NCT06769126
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Phase 3
Not yet recruiting
- Conditions
- Pancreatic CarcinomaPancreatic Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Distal PancreatectomyOther: Questionnaire AdministrationOther: Saline
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 274
- Registration Number
- NCT06807437
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Phase 2
Not yet recruiting
- Conditions
- CD19+ Acute LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 55
- Registration Number
- NCT06773936
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Phase 2
Recruiting
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 378
- Registration Number
- NCT06616584
- Locations
- 🇺🇸
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
🇺🇸Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Phase 3
Recruiting
- Conditions
- Stage IVB Prostate Cancer AJCC v8Castration-Resistant Prostate Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 528
- Registration Number
- NCT06470243
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Phase 2
Recruiting
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 88
- Registration Number
- NCT06116682
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Phase 2
Recruiting
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: LymphoscintigraphyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT06031688
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States
🇺🇸Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States
🇺🇸Northwestern Medicine Glenview Outpatient Center, Glenview, Illinois, United States
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Phase 3
Recruiting
- Conditions
- AL Amyloidosis
- Interventions
- Procedure: Biospecimen CollectionProcedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Stem Cell IsolationProcedure: EchocardiographyOther: Survey AdministrationProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 338
- Registration Number
- NCT06022939
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center-South County, Saint Louis, Missouri, United States
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Phase 3
Recruiting
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Early Stage Triple-Negative Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: Surgical Procedure
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 2400
- Registration Number
- NCT05929768
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Phase 2
Recruiting
- Conditions
- Refractory Diffuse Large B-Cell LymphomaHigh Grade B-Cell LymphomaTransformed Non-Hodgkin LymphomaGrade 3b Follicular LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 227
- Registration Number
- NCT05890352
- Locations
- 🇺🇸
SWOG, Portland, Oregon, United States
🇺🇸Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
🇺🇸Saint Joseph Mercy Brighton, Brighton, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath